FIELD: medicine.
SUBSTANCE: invention relates to biotechnology and represents pharmaceutical compositions and method for treatment of diseases associated with amyloid depositions Aβ in patient's brain, such as Alzheimer's disease. Method includes introduction of immunogenic fragment Aβ with absence of T-cell epitope, able to induce effective immune response in form of antibodies to Aβ. Pharmaceutical compositions include immunogenic fragment, chemically bound with carrier molecule, which can be introduced with adjuvant.
EFFECT: invention is efficient as vaccine against Alzheimer's disease.
18 cl, 13 dwg, 9 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIGEN TAU-PEPTIDES AND THEIR APPLICATION | 2010 |
|
RU2518291C2 |
| VACCINE COMPOSITION FOR CONTROLLING INFESTATION WITH ECTOPARASITES | 2011 |
|
RU2585226C2 |
| ACTIVE IMMUNISATION FOR CREATING SOLUBLE A-BETA ANTIBODIES | 2004 |
|
RU2390350C2 |
| NON-LIPIDISED VARIANTS OF NEISSERIA MENINGITIDIS ORF2086 ANTIGENS | 2011 |
|
RU2546873C2 |
| PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF DEMENTIA OF THE ALZHEIMER'S TYPE | 2013 |
|
RU2696566C2 |
| IMMUNOGENIC COMPOSITIONS AND METHODS | 2008 |
|
RU2468034C2 |
| VACCINE COMPOSITION AND USE THEREOF | 2016 |
|
RU2726411C2 |
| PCSK9 VACCINES | 2015 |
|
RU2698971C2 |
| IMMUNOGEN PEPTIDE AGAINST GROUP A STREPTOCOCCI | 2018 |
|
RU2775621C2 |
| PEPTIDE IMMUNOGENS AND COMPOSITIONS CONTAINING SAID IMMUNOGENS TARGETING MEMBRANE-BOUND IGE FOR TREATING IGE-MEDIATED ALLERGIC DISEASES | 2017 |
|
RU2769983C2 |
